In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?

Would you consider neoadjuvant cisplatin-based therapy before trimodality therapy, and would you incorporate Durvalumab per the NIAGARA protocol?